SCHEMBL4185556

SCHEMBL4185556

CSC(=N)Nc1cccc([N+](=O)[O-])c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.63
KMT2A Q03164 7/20 0.62
MEN1 O00255 6/20 0.62
MAPT P10636 6/20 0.62
POLB P06746 3/20 0.62
HTT P42858 2/20 0.62
DDX3X O00571 1/20 0.62
CTDSP1 Q9GZU7 1/20 0.62
ALDH1A1 P00352 6/20 0.58
BLM P54132 1/20 0.56
BAZ1A Q9NRL2 1/20 0.56
GAA P10253 1/20 0.55
MAPK1 P28482 2/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA5A P35218 1/20 0.52
CA9 Q16790 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
HSP90AA1 P07900 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7865709 0.83 SMN1; SMN2 (0.73) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL6725074 0.82 KMT2A (0.72) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL27699195 0.82 KMT2A (0.59) SMN1; SMN2KMT2AMEN1MAPTPOLB
Iodide SCHEMBL8618697 0.81 KMT2A (0.58) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL1592991 0.80 KMT2A (0.68) SMN1; SMN2KMT2AMEN1MAPTPOLB
Hydrochloric Acid SCHEMBL1592637 0.78 KMT2A (0.66) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL12523964 0.78 SMN1; SMN2 (0.76) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL1248559 0.78 SMN1; SMN2 (1.00) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL1047211 0.77 MEN1 (1.00) SMN1; SMN2KMT2AMEN1MAPTPOLB
Nitric Acid SCHEMBL2283510 0.77 KMT2A (0.64) SMN1; SMN2KMT2AMEN1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL SMN1; SMN2 1114/4885KMT2A 2240/4885MEN1 543/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL SMN1; SMN2 1114/4885KMT2A 2240/4885MEN1 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.